

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

---

BRISTOL-MYERS SQUIBB COMPANY,  
AND PFIZER INC.,

Plaintiffs,

v.

BRECKENRIDGE PHARMACEUTICAL,  
INC.,

Defendant.

---

Civil Action No. \_\_\_\_\_

**COMPLAINT**

Plaintiffs Bristol-Myers Squibb Company (“BMS”) and Pfizer Inc. (“Pfizer”) (BMS and Pfizer, collectively, “Plaintiffs”), by their attorneys, hereby allege as follows:

**NATURE OF THE ACTION**

1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, against Defendant Breckenridge Pharmaceutical, Inc. (“Breckenridge”). This action relates to Abbreviated New Drug Application (“ANDA”) No. 209845 filed by Breckenridge with the U.S. Food and Drug Administration (“FDA”).

2. In ANDA No. 209845, Breckenridge seeks approval to market 2.5 mg and 5 mg tablets of apixaban, generic versions of Plaintiffs’ Eliquis® drug product (the “Breckenridge ANDA product”), prior to expiration of U.S. Patent No. 9,326,945 (the “’945 patent” or “patent-in-suit”).

### **PARTIES**

3. BMS is a corporation organized and existing under the laws of Delaware, having a place of business at Route 206 and Province Line Road, Princeton, New Jersey 08540.

4. Pfizer is a corporation organized and existing under the laws of Delaware, having its principal place of business at 235 East 42nd Street, New York, New York 10017.

5. Plaintiffs are engaged in the business of creating, developing, and bringing to market revolutionary pharmaceutical products to help patients prevail against serious diseases, including treatments for thromboembolic disorders. Plaintiffs sell Eliquis<sup>®</sup> in this judicial district and throughout the United States.

6. Upon information and belief, Breckenridge is a corporation organized and existing under the laws of Florida, having its principal place of business at 6111 Broken Sound Parkway NW, Suite 170, Boca Raton, Florida 33487.

### **JURISDICTION AND VENUE**

7. This action arises under the patent laws of the United States, 35 U.S.C. §§ 100, *et seq.*, and this Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

8. Venue is proper in this Court under 28 U.S.C. §§ 1391 and/or 1400(b), and this Court has personal jurisdiction over Breckenridge. Breckenridge, through its counsel, by e-mail dated March 10, 2017, agreed that it does not contest jurisdiction or venue in this Court in this matter.

### **PATENT-IN-SUIT**

9. On May 3, 2016, the U.S. Patent and Trademark Office duly and legally issued the '945 patent, titled "Apixaban Formulations." A true and correct copy of the '945 patent is

attached hereto as Exhibit A. The claims of the '945 patent are valid, enforceable, and not expired. Plaintiffs are the joint owners of the '945 patent and have the right to enforce it.

10. BMS is the holder of New Drug Application (“NDA”) No. 202155, by which the FDA granted approval for the marketing and sale of 2.5 mg and 5 mg strength apixaban tablets. Plaintiffs market apixaban tablets in the United States, under the trade name “Eliquis®.” The FDA’s official publication of approved drugs (the “Orange Book”) includes Eliquis® together with the patent-in-suit. Eliquis® is a factor Xa inhibitor indicated: (1) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; (2) for the prophylaxis of deep vein thrombosis (“DVT”), which may lead to pulmonary embolism (“PE”), in patients who have undergone hip or knee replacement surgery; and (3) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. A copy of the complete prescribing information for Eliquis® approved in NDA No. 202155 is attached as Exhibit B.

#### **INFRINGEMENT BY BRECKENRIDGE**

11. By letter sent by Federal Express on February 23, 2017, Breckenridge notified Plaintiffs that Breckenridge had submitted ANDA No. 209845 to the FDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(j)) (“the Eliquis Notice Letter”). Plaintiffs received the Eliquis Notice Letter no earlier than February 24, 2017.

12. The Eliquis Notice Letter states that Breckenridge seeks approval from the FDA to engage in the commercial manufacture, use, and sale of the Breckenridge ANDA product before the expiration of the patent-in-suit. Upon information and belief, Breckenridge intends to – directly or indirectly – engage in the commercial manufacture, use, and sale of the Breckenridge ANDA product promptly upon receiving FDA approval to do so.

13. By filing ANDA No. 209845, Breckenridge has necessarily represented to the FDA that the Breckenridge ANDA product has the same active ingredient as Eliquis<sup>®</sup>, has the same dosage form and strength as Eliquis<sup>®</sup>, and is bioequivalent to Eliquis<sup>®</sup>.

14. Upon information and belief, Breckenridge is seeking approval to market the Breckenridge ANDA product for the same approved indications as Eliquis<sup>®</sup>.

15. In the Eliquis Notice Letter, Breckenridge states that its ANDA contains a certification pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) asserting that the patent-in-suit is invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, and sale of the Breckenridge ANDA product.

16. In the Eliquis Notice Letter, Breckenridge offered confidential access to portions of its ANDA No. 209845 on terms and conditions set forth in the Eliquis Notice Letter (“the Breckenridge Offer”). Breckenridge requested that Plaintiffs accept the Breckenridge Offer before receiving access to Breckenridge’s ANDA No. 209845. The Breckenridge Offer contained unreasonable restrictions well beyond those that would apply under a protective order on who could view the ANDA. For example, the Breckenridge Offer contained a broad patent prosecution bar, which, among other things, does not have a carve-out for inter-partes reviews or other adversarial proceedings, and a broad bar on any work related to actions before the FDA. The Breckenridge Offer unreasonably restricted the ability of counsel to seek the opinions of Plaintiffs’ employees and outside experts without written permission from Breckenridge’s designated counsel; and Breckenridge had broad authority to reject any request by Plaintiffs to seek outside expert access to the Breckenridge ANDA. The restrictions Breckenridge has placed on access to ANDA No. 209845 contravene 21 U.S.C. § 355(j)(5)(C)(i)(III), which states that an offer of confidential access “shall contain such restrictions as to persons entitled to access, and on

the use and disposition of any information accessed, *as would apply had a protective order been entered for the purpose of protecting trade secrets and other confidential business information*” (emphasis added).

17. This Complaint is being filed before the expiration of forty-five days from the date Plaintiffs received the Eliquis Notice Letter.

## **COUNT I**

### **(INFRINGEMENT OF THE '945 PATENT)**

18. Each of the preceding paragraphs 1 to 17 is incorporated as if fully set forth herein.

19. Breckenridge’s submission of ANDA No. 209845 to obtain approval to engage in the commercial manufacture, use, offer to sell, or sale of the Breckenridge ANDA product prior to the expiration of the ’945 patent constituted a technical act of infringement of at least one of the claims of the ’945 patent, either literally or under the doctrine of equivalents, including but not limited to claims 1, 9-12, 20-23, 25, 27, 29, 31, 33, 35, and 37, under 35 U.S.C. § 271(e)(2)(A).

20. Breckenridge’s commercial manufacture, use, offer to sell, sale, or importation of the Breckenridge ANDA product prior to the expiration of the ’945 patent, and its inducement of and/or contribution to such conduct, would further infringe at least one of the claims of the ’945 patent, either literally or under the doctrine of equivalents, including but not limited to claims 1, 9-12, 20-23, 25, 27, 29, 31, 33, 35, and 37, under 35 U.S.C. §§ 271(a), (b) and/or (c).

21. Upon FDA approval of Breckenridge’s ANDA No. 209845, Breckenridge will infringe one or more claims of the ’945 patent, either literally or under the doctrine of equivalents, including but not limited to claims 1, 9-12, 20-23, 25, 27, 29, 31, 33, 35, and 37, by making, using, offering to sell, and selling the Breckenridge ANDA product in the United States and/or importing said product into the United States, or by actively inducing and contributing to infringement of the ’945 patent by others, under 35 U.S.C. § 271(a)-(c), unless enjoined by the Court.

22. If Breckenridge's marketing and sale of the Breckenridge ANDA product prior to expiration of the '945 patent and all other relevant exclusivities are not enjoined, Plaintiffs will suffer substantial and irreparable harm for which there is no remedy at law.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs pray that this Court grant the following relief:

1. A judgment that the claims of the patent-in-suit are not invalid, are not unenforceable, and are infringed by Breckenridge's submission of ANDA No. 209845, either literally or under the doctrine of equivalents, and that Breckenridge's making, using, offering to sell, or selling in the United States, or importing into the United States the Breckenridge ANDA product will infringe the claims of the patent-in-suit, either literally or under the doctrine of equivalents.

2. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any approval of ANDA No. 209845 shall be a date which is not earlier than the latest expiration date of the patent-in-suit, including any extensions and/or additional periods of exclusivity to which Plaintiffs are or become entitled.

3. An order permanently enjoining Breckenridge, its affiliates, subsidiaries, and each of its officers, agents, servants and employees and those acting in privity or concert with them, from making, using, offering to sell, or selling in the United States, or importing into the United States the Breckenridge ANDA product until after the latest expiration date of the patent-in-suit, including any extensions and/or additional periods of exclusivity to which Plaintiffs are or become entitled.

4. Damages or other monetary relief, including costs, fees, pre and post-judgment interest, to Plaintiffs if Breckenridge engages in commercial manufacture, use, offers to sell, sale, or importation in or into the United States of the Breckenridge ANDA product

prior to the latest expiration date of the patent-in-suit, including any extensions and/or additional periods of exclusivity to which Plaintiffs are or become entitled.

5. Such further and other relief as this Court deems proper and just, including any appropriate relief under 35 U.S.C. § 285.

Dated: April 5, 2017

Respectfully submitted,

Of Counsel:

FARNAN LLP

Amy K. Wigmore  
Gregory H. Lantier  
Tracey C. Allen  
Heather M. Petruzzi  
Jeffrey T. Hantson  
Wilmer Cutler Pickering Hale and Dorr LLP  
1875 Pennsylvania Ave, NW  
Washington, DC 20006  
202-663-6000  
202-663-6363

/s/ Michael J. Farnan  
Joseph J. Farnan, Jr. (Bar No. 100245)  
Brian E. Farnan (Bar No. 4089)  
Michael J. Farnan (Bar No. 5165)  
919 N. Market Str., 12<sup>th</sup> Floor  
Wilmington, DE 19801  
Tel: (302) 777-0300  
Fax: (302) 777-0301  
farnan@farnanlaw.com  
bfarnan@farnanlaw.com  
mfarnan@farnanlaw.com

*Counsel for Plaintiffs Bristol-Myers Squibb  
Company and Pfizer Inc.*